Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE; AIDS Clinical Trials Group A5088 Protocol Team. Glesby MJ, et al. Among authors: fichtenbaum c. J Infect Dis. 2005 Mar 1;191(5):686-93. doi: 10.1086/427812. Epub 2005 Jan 26. J Infect Dis. 2005. PMID: 15688281 Clinical Trial.
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Dubé MP, et al. Clin Infect Dis. 2003 Sep 1;37(5):613-27. doi: 10.1086/378131. Epub 2003 Aug 15. Clin Infect Dis. 2003. PMID: 12942391 Review. No abstract available.
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. Goldman M, et al. Clin Infect Dis. 2004 May 15;38(10):1485-9. doi: 10.1086/420749. Epub 2004 Apr 28. Clin Infect Dis. 2004. PMID: 15156489
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. Aberg JA, et al. AIDS Res Hum Retroviruses. 2005 Sep;21(9):757-67. doi: 10.1089/aid.2005.21.757. AIDS Res Hum Retroviruses. 2005. PMID: 16218799 Clinical Trial.
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes WE, Filler SG; AIDS Clinical Trials Group Study Team 323; Mycoses Study Group Study Team 40. Goldman M, et al. Among authors: fichtenbaum cj. Clin Infect Dis. 2005 Nov 15;41(10):1473-80. doi: 10.1086/497373. Epub 2005 Oct 12. Clin Infect Dis. 2005. PMID: 16231260 Clinical Trial.
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.
Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Wohl DA, et al. Among authors: fichtenbaum c. Clin Infect Dis. 2006 Sep 1;43(5):645-53. doi: 10.1086/507333. Epub 2006 Jul 27. Clin Infect Dis. 2006. PMID: 16886161 Review.
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. Jacobson JM, et al. Among authors: fichtenbaum cj. J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169. J Infect Dis. 2008. PMID: 18771406 Clinical Trial.
204 results